• RejuvenAir® Development Status

    CSA Medical is committed to making advancements that improve the lives of people suffering from chronic bronchitis, and believe that the underlying symptoms of chronic bronchitis can be reversed by applying liquid nitrogen to diseased tissue within the lungs.

    We are advancing our core liquid nitrogen spray technology to target the mucous-producing goblet cells and epithelial layer within the lungs. With the destruction of these unwanted cells in a non-scarring way, the body can begin the rapid process of regrowth of new healthy cells in its place.

    We are currently conducting clinical studies with the RejuvenAir System to determine the extent of reduction in mucus production and inflammation and the subsequent overall improvement to the health and quality of life of chronic bronchitis patients.


    The RejuvenAir® System is currently under clinical investigation and is not commercially available.